Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of DBPR108 100 mg in patients with Type 2 Diabetes Mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• DBPR108 (DBPR108)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED